65 related articles for article (PubMed ID: 1370648)
1. The human prostatic carcinoma cell line LNCaP expresses biologically active, specific receptors for 1 alpha,25-dihydroxyvitamin D3.
Miller GJ; Stapleton GE; Ferrara JA; Lucia MS; Pfister S; Hedlund TE; Upadhya P
Cancer Res; 1992 Feb; 52(3):515-20. PubMed ID: 1370648
[TBL] [Abstract][Full Text] [Related]
2. Discordant Health Implications and Molecular Mechanisms of Vitamin D in Clinical and Preclinical Studies of Prostate Cancer: A Critical Appraisal of the Literature Data.
Fendler A; Stephan C; Ralla B; Jung K
Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791324
[TBL] [Abstract][Full Text] [Related]
3. The complex interplay of modifiable risk factors affecting prostate cancer disparities in African American men.
Johnson JR; Mavingire N; Woods-Burnham L; Walker M; Lewis D; Hooker SE; Galloway D; Rivers B; Kittles RA
Nat Rev Urol; 2024 Feb; ():. PubMed ID: 38307952
[TBL] [Abstract][Full Text] [Related]
4. Dietary Carcinogens and DNA Adducts in Prostate Cancer.
Bellamri M; Turesky RJ
Adv Exp Med Biol; 2019; 1210():29-55. PubMed ID: 31900903
[TBL] [Abstract][Full Text] [Related]
5. The Association of a Novel Identified
Daremipouran MR; Beyene D; Apprey V; Naab TJ; Kassim OO; Copeland RL; Kanaan YM
Cancer Genomics Proteomics; 2019; 16(4):245-255. PubMed ID: 31243105
[TBL] [Abstract][Full Text] [Related]
6. Updated analysis of vitamin D receptor gene FokI polymorphism and prostate cancer susceptibility.
Mi YY; Chen YZ; Chen J; Zhang LF; Zuo L; Zou JG
Arch Med Sci; 2017 Oct; 13(6):1449-1458. PubMed ID: 29181077
[TBL] [Abstract][Full Text] [Related]
7. Interactions of the Insulin-Like Growth Factor Axis and Vitamin D in Prostate Cancer Risk in the Prostate Cancer Prevention Trial.
Miles FL; Goodman PJ; Tangen C; Torkko KC; Schenk JM; Song X; Pollak M; Thompson IM; Neuhouser ML
Nutrients; 2017 Apr; 9(4):. PubMed ID: 28417914
[TBL] [Abstract][Full Text] [Related]
8. Association of VDR polymorphisms ( Taq I and Bsm I) with prostate cancer: a new meta-analysis.
Liu S; Cai H; Cheng W; Zhang H; Pan Z; Wang D
J Int Med Res; 2017 Feb; 45(1):3-10. PubMed ID: 28222630
[TBL] [Abstract][Full Text] [Related]
9. Systems analysis of the prostate transcriptome in African-American men compared with European-American men.
Hardiman G; Savage SJ; Hazard ES; Wilson RC; Courtney SM; Smith MT; Hollis BW; Halbert CH; Gattoni-Celli S
Pharmacogenomics; 2016 Jul; 17(10):1129-1143. PubMed ID: 27359067
[TBL] [Abstract][Full Text] [Related]
10. The Use of 1α,25-Dihydroxyvitamin D₃ as an Anticancer Agent.
Marcinkowska E; Wallace GR; Brown G
Int J Mol Sci; 2016 May; 17(5):. PubMed ID: 27187375
[TBL] [Abstract][Full Text] [Related]
11. Associations Between Serum Vitamin D and Adverse Pathology in Men Undergoing Radical Prostatectomy.
Nyame YA; Murphy AB; Bowen DK; Jordan G; Batai K; Dixon M; Hollowell CM; Kielb S; Meeks JJ; Gann PH; Macias V; Kajdacsy-Balla A; Catalona WJ; Kittles R
J Clin Oncol; 2016 Apr; 34(12):1345-9. PubMed ID: 26903577
[TBL] [Abstract][Full Text] [Related]
12. Serum 25-hydroxyvitamin D concentrations and risk of prostate cancer: results from the Prostate Cancer Prevention Trial.
Schenk JM; Till CA; Tangen CM; Goodman PJ; Song X; Torkko KC; Kristal AR; Peters U; Neuhouser ML
Cancer Epidemiol Biomarkers Prev; 2014 Aug; 23(8):1484-93. PubMed ID: 25085836
[TBL] [Abstract][Full Text] [Related]
13. Vitamin D receptor as a therapeutic target for benign prostatic hyperplasia.
Manchanda PK; Kibler AJ; Zhang M; Ravi J; Bid HK
Indian J Urol; 2012 Oct; 28(4):377-81. PubMed ID: 23450267
[TBL] [Abstract][Full Text] [Related]
14. Phase II open label, multi-center clinical trial of modulation of intermediate endpoint biomarkers by 1α-hydroxyvitamin D2 in patients with clinically localized prostate cancer and high grade pin.
Gee J; Bailey H; Kim K; Kolesar J; Havighurst T; Tutsch KD; See W; Cohen MB; Street N; Levan L; Jarrard D; Wilding G
Prostate; 2013 Jun; 73(9):970-8. PubMed ID: 23335089
[TBL] [Abstract][Full Text] [Related]
15. Calcium and vitamin D supplementation during androgen deprivation therapy for prostate cancer: a critical review.
Datta M; Schwartz GG
Oncologist; 2012; 17(9):1171-9. PubMed ID: 22836449
[TBL] [Abstract][Full Text] [Related]
16. Impaired vitamin D activation and association with CYP24A1 haplotypes in differentiated thyroid carcinoma.
Penna-Martinez M; Ramos-Lopez E; Stern J; Kahles H; Hinsch N; Hansmann ML; Selkinski I; Grünwald F; Vorländer C; Bechstein WO; Zeuzem S; Holzer K; Badenhoop K
Thyroid; 2012 Jul; 22(7):709-16. PubMed ID: 22690899
[TBL] [Abstract][Full Text] [Related]
17. Vitamin D3 supplementation at 4000 international units per day for one year results in a decrease of positive cores at repeat biopsy in subjects with low-risk prostate cancer under active surveillance.
Marshall DT; Savage SJ; Garrett-Mayer E; Keane TE; Hollis BW; Horst RL; Ambrose LH; Kindy MS; Gattoni-Celli S
J Clin Endocrinol Metab; 2012 Jul; 97(7):2315-24. PubMed ID: 22508710
[TBL] [Abstract][Full Text] [Related]
18. Predictors of serum vitamin D levels in African American and European American men in Chicago.
Murphy AB; Kelley B; Nyame YA; Martin IK; Smith DJ; Castaneda L; Zagaja GJ; Hollowell CM; Kittles RA
Am J Mens Health; 2012 Sep; 6(5):420-6. PubMed ID: 22398989
[TBL] [Abstract][Full Text] [Related]
19. Vitamin D metabolism and action in the prostate: implications for health and disease.
Swami S; Krishnan AV; Feldman D
Mol Cell Endocrinol; 2011 Dec; 347(1-2):61-9. PubMed ID: 21664249
[TBL] [Abstract][Full Text] [Related]
20. Serum 25-OH vitamin D levels and risk of developing prostate cancer in older men.
Barnett CM; Nielson CM; Shannon J; Chan JM; Shikany JM; Bauer DC; Hoffman AR; Barrett-Connor E; Orwoll E; Beer TM
Cancer Causes Control; 2010 Aug; 21(8):1297-303. PubMed ID: 20383574
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
